SynthesisAnnals of medicine2025
Diagnostic performance of PAX1 methylation as a biomarker for cervical lesions: a clinical study and meta-analysis.
Synthesis in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Paired box 1 gene methylation as a promising triage strategy for atypical squamous cells: a retrospective comparison with high-risk HPV testing in cervical cancer screening.Infectious agents and cancer · 2026Article
- Epigenetic, Genetic, and Functional Germline Alterations ofCurrent issues in molecular biology · 2026Review
- Integrating Biomarkers into Cervical Cancer Screening-Advances in Diagnosis and Risk Prediction: A Narrative Review.Diagnostics (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the diagnostic performance of PAX1 gene methylation in the detection of cervical lesions and assess its potential clinical application in cervical cancer screening through both a single-centre study and a meta-analysis.
methodsA retrospective analysis was conducted on 329 patients who underwent concurrent ThinPrep cytologic test (TCT), high-risk HPV testing and PAX1 methylation analysis at the Affiliated Hospital of Jining Medical University. The diagnostic accuracy of PAX1 methylation for detecting high-grade squamous intraepithelial lesions (HSIL) and cervical squamous cell carcinoma (CSCC) was assessed. Additionally, we performed a systematic review and meta-analysis, which included seven eligible studies from Asian populations. Pooled diagnostic metrics were calculated using a bivariate mixed-effects model. Heterogeneity and publication bias were evaluated using Cochran's Q test, I
resultsPAX1 methylation values declined with increasing severity of cervical lesions. In clinical samples, the sensitivity and specificity for detecting CSCC were 81.3% and 94.2%, respectively. Meta-analysis yielded a pooled sensitivity of 0.87 (95% CI: 0.79-0.92), specificity of 0.75 (95% CI: 0.52-0.89) and an area under the curve (AUC) of 0.89. The diagnostic odds ratio was 20, indicating strong discriminatory performance.
conclusionPAX1 methylation demonstrates high diagnostic accuracy for cervical cancer and is a promising noninvasive biomarker for screening and triage. Further studies are needed to validate its clinical utility in diverse populations and to explore its potential role in monitoring lesion progression or regression, particularly in women managed with conservative approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.